Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Beremagene geperpavec is gene therapy used to treat wounds associated with dystrophic epidermolysis bullosa. Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy.
- Mechanism
- Curator reviewed · 8 references
Collagen VII (C7, COL7), encoded by the COL7A1 gene, is an anchoring fibril component that holds the epidermis and dermis together to maintain skin integrity. COL7 is synthesized by epidermal keratinocytes and dermal fibroblasts. Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by COL7A1 gene mutations, leading to reduced or deficient levels of biologically active and functional COL7. Deficient levels of COL7 result in no functional anchoring fibrils and impaired dermal-epidermal adhesion. DEB is associated with blistering, wounding, and scarring of the skin and other organs starting at birth.
Beremagene geperpavec is a herpes simplex virus type 1 (HSV-1)-based vector genetically modified to express COL7. Upon topical application to wounds, beremagene geperpavec enters both keratinocytes and fibroblasts and the vector genome is deposited in the nucleus. Once in the nucleus, transcription of the encoded human COL7A1 is initiated to produce and secrete COL7 by the cell in its mature form. COL7 molecules arrange themselves into long, thin bundles that form anchoring fibrils.
- Primary indication
- Beremagene geperpavec (Vyjuvek) is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, in individuals from birth.Curator reviewed · 2 structured indications
- First approval
- United States, 2023
- Also known as
- B-VEC · Bercolagene telserpavec · BVEC · Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
- Code names
- KB-103 · KB803
- Brand names
- Vyjuvek
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Beremagene geperpavec, and which of those have an active Phase 3 trial?